Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Royal Bank of Canada

Royal Bank of Canada increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 332,300 shares of the company’s stock after acquiring an additional 21,288 shares during the quarter. Royal Bank of Canada’s holdings in Neurocrine Biosciences were worth $43,777,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in NBIX. DJE Kapital AG acquired a new position in shares of Neurocrine Biosciences during the fourth quarter worth approximately $28,000. Geneos Wealth Management Inc. increased its position in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the period. Meeder Asset Management Inc. raised its stake in Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after acquiring an additional 202 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in Neurocrine Biosciences during the 1st quarter worth $33,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Neurocrine Biosciences during the 4th quarter worth $39,000. 92.59% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $157.65, for a total value of $2,364,750.00. Following the completion of the sale, the director owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. The trade was a 30.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen A. Sherwin sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the completion of the sale, the director directly owned 15,860 shares of the company’s stock, valued at $2,621,975.20. This represents a 61.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 395,422 shares of company stock valued at $62,448,693 over the last 90 days. 4.60% of the stock is owned by corporate insiders.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong Q2 performance: Second-quarter revenue rose 39% year over year to $959 million, exceeding the approximately $891 million analyst estimate. Adjusted earnings were $2.85 per share versus the $2.26 consensus, while net income increased to $144.4 million. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Product and pipeline growth: INGREZZA sales increased 15% to $716 million, while CRENESSITY generated $184 million and newly acquired VYKAT XR contributed $54 million. Neurocrine also raised its 2026 INGREZZA sales guidance to $2.825 billion-$2.875 billion, supporting the company’s commercial outlook and Soleno Therapeutics acquisition. NBIX Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support strengthened: TD Cowen, Guggenheim, Stifel, Cantor Fitzgerald, Piper Sandler, Needham, RBC and Morgan Stanley all raised their price targets, with targets ranging from $196 to $222. William Blair also reiterated a Buy rating, citing strong execution and substantial pipeline potential. Analyst Price Target Updates
• Neutral Sentiment: Investor expectations remain elevated: Although NBIX beat quarterly estimates, the market appears to have wanted a larger revenue upside surprise or more aggressive full-year guidance. The reaction suggests investors may be reassessing how much near-term upside is already reflected in the shares.
• Negative Sentiment: Insider selling adds a cautionary signal: Director Leslie Norwalk sold 1,250 shares for about $228,000 under a pre-arranged Rule 10b5-1 plan. Broader data also show numerous insider sales and no open-market purchases over the past six months, though such transactions may be planned and do not necessarily indicate deteriorating fundamentals. SEC Insider Trading Filing

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $166.80 on Monday. The business’s 50-day moving average price is $167.81 and its 200 day moving average price is $146.50. The stock has a market capitalization of $16.77 billion, a P/E ratio of 24.46, a P/E/G ratio of 0.70 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Guggenheim upped their price objective on shares of Neurocrine Biosciences from $200.00 to $222.00 and gave the stock a “buy” rating in a report on Friday. Citigroup raised their price objective on shares of Neurocrine Biosciences from $246.00 to $249.00 and gave the company a “buy” rating in a research note on Friday. BMO Capital Markets increased their price target on Neurocrine Biosciences from $144.00 to $170.00 and gave the company a “market perform” rating in a research note on Monday, July 13th. Wedbush upped their price objective on Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Finally, Needham & Company LLC lifted their target price on Neurocrine Biosciences from $200.00 to $204.00 and gave the stock a “buy” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.64.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.